INS and type 2 diabetes mellitus: Several workers have demonstrated the following actions of vildagliptin in T2DM patients: it reduces glycosylated-hemoglobin [HbA(1)c] in T2DM patients whose blood sugar is poorly controlled even with high doses of insulin.